🟠 Moderate Evidence
Each dollar invested in Helicobacter pylori screening generates approximately five dollars in gastric cancer prevention benefits, according to a new health economics analysis. This cost-benefit finding strengthens the case for wider adoption of screening programmes in populations at elevated risk, particularly in regions where gastric cancer remains a leading malignancy.
Key takeaways
- H. pylori screening demonstrates a 5:1 return on investment in gastric cancer prevention
- Economic analysis supports screening as a cost-effective public health intervention
- Findings particularly relevant for high-incidence gastric cancer regions, including parts of East Asia and Eastern Europe
Study at a Glance
| Evidence type | Health economics analysis and cost-benefit evaluation |
| Focus | Return on investment from H. pylori screening programmes |
| Key metric | Cost-benefit ratio: 1:5 (investment to prevention value) |
| Clinical relevance | Gastric cancer prevention and screening strategy prioritization |
| Application | Global health policy and resource allocation |
Return on investment: H. pylori screening versus other cancer prevention interventions
Cost-benefit ratios for selected cancer screening programmes (higher bars indicate better value)
Source: Health economics analysis, 2026 | Georgian Medical Journal News
The case for H. pylori eradication as prevention strategy
Helicobacter pylori infection is a established risk factor for gastric cancer, with the bacterium classified as a Group 1 carcinogen by the International Agency for Research on Cancer (IARC). The bacterium colonises the gastric mucosa and can persist for decades, initiating a cascade of chronic inflammation that progresses through intestinal metaplasia and dysplasia toward malignancy.
The economic analysis demonstrates that screening and treating H. pylori before precancerous changes develop represents a high-value intervention. This aligns with WHO guidance on cancer prevention, which emphasises early detection and removal of risk factors as cornerstone strategies for reducing cancer burden in resource-limited settings.
Geographic burden and screening implications
Gastric cancer remains the fifth leading cause of cancer mortality globally, with approximately 769,000 deaths reported annually according to recent epidemiological estimates. Incidence varies sharply by geography: East Asia, Eastern Europe, and parts of Latin America report the highest age-standardised rates, driven partly by higher H. pylori prevalence in these regions.
For countries with gastric cancer incidence exceeding 20 cases per 100,000 per year—a threshold often used to justify screening programmes—the fivefold return on screening investment carries substantial implications. A single screening campaign reaching high-risk populations could prevent hundreds of cases per 100,000 screened, yielding both mortality reduction and long-term healthcare savings.
This economic case strengthens arguments within the Health Policy community for integrating H. pylori screening into national cancer control plans. Resources previously spent on treating advanced gastric cancer—requiring surgery, chemotherapy, and palliative care—can be redirected toward prevention.
Treatment accessibility and health equity considerations
The five-to-one return ratio assumes that screened-positive individuals have access to effective eradication therapy. Standard regimens combining proton pump inhibitors with antibiotics remain effective but face affordability and resistance challenges in low-income settings. Overcoming these barriers—through improved diagnostics, fixed-dose combinations, and generic availability—is essential to realising the economic benefits demonstrated in the analysis.
Each unit of cost invested in H. pylori screening generates approximately five units of value in gastric cancer prevention benefits, supporting screening as a cost-effective public health intervention across high-incidence regions.
— Health economics analysis, 2026
What this means
Frequently asked questions
Who should be screened for H. pylori?
Current evidence supports screening for individuals aged 40–60 years in regions with high gastric cancer incidence, and for those with family history of gastric cancer regardless of geography. Clinical guidelines increasingly recommend population-based screening in countries where gastric cancer incidence exceeds 20 per 100,000 annually.
How is H. pylori screening performed?
Screening commonly uses non-invasive serology (blood antibody testing) or urea breath tests. Endoscopy with biopsy remains the reference standard but is reserved for symptomatic individuals or those with positive screening results, reducing overall programme costs.
What is the treatment success rate for H. pylori eradication?
Standard triple or quadruple therapy regimens achieve eradication rates of 85–95% in most populations, according to clinical trial data. Resistance patterns vary geographically, requiring region-specific treatment protocols.
As healthcare systems increasingly adopt value-based purchasing and cost-effectiveness frameworks, H. pylori screening programmes are gaining traction in both high-income and middle-income countries. The fivefold return on investment provides a quantitative benchmark for comparing screening priorities, supporting decision-makers who must allocate finite resources across competing cancer prevention strategies. Further research quantifying implementation costs in diverse healthcare settings will refine these estimates and accelerate global programme rollout.
Source: H. pylori screening could return fivefold value in gastric cancer prevention
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
